Outbreak of Klebsiella pneumoniae carbapenemase-2-producing K. pneumoniae sequence type 11 in Taiwan in 2011

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5016-5022

  Lee, Chun Ming ^a,b,c   Liao, Chun Hsing ^d   Lee, Wen Sen ^e   Liu, Yung Ching ^f   Mu, Jung Jung ^g   Lee, Meng Chih ^a,h   Hsueh, Po Ren ⁱ  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^d FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^g CENTER FOR DISEASE CONTROL   (Taiwan)

^h Taichung Hospital   (Taiwan)

ⁱ NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; CARBAPENEMASE; CEFEPIME; COLISTIN; COTRIMOXAZOLE; DORIPENEM; ERTAPENEM; FOSFOMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; TIGECYCLINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; GENOTYPE; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; TAIWAN;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CITROBACTER FREUNDII; ELECTROPHORESIS, GEL, PULSED-FIELD; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; GENOTYPE; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; POLYMERASE CHAIN REACTION;

EID: 84866335444     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00878-12     Document Type: Article

References (39)

1. Alhambra A, Cuadros JA, Cacho J, Gómez-Garcés JL, Alós JI. 2004. In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. J. Antimicrob. Chemother. 53:1090-1094. (Pubitemid 38807655)
2. Balm MN, Ngan G, Jureen R, Lin RT, Teo J. 2012. Molecular characterization of newly emerged blaKPC-2-producing Klebsiella pneumoniae in Singapore. J. Clin. Microbiol. 50:475-476.
3. Bratu S, et al. 2005. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch. Intern. Med. 165:1430-1435. (Pubitemid 40973427)
4. Bratu S, et al. 2005. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob. Agents Chemother. 49:3018-3020. (Pubitemid 40917631)
5. Centers for Disease Control and Prevention. 2009. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb. Mortal. Wkly. Rep. 58:256-260.
6. Centers for Disease Control and Prevention. 2011. Carbapenem-resistant Klebsiella pneumoniae associated with a long-term-care facility-West Virginia, 2009-2011. MMWR Morb. Mortal. Wkly. Rep. 60:1418-1420.
7. Chen M, Nafziger AN, Drusano GL, Ma L, Bertino JS, Jr. 2006. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob. Agents Chemother. 50:1222-1227.
8. Chen YH, et al. 2011. Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intraabdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria. J. Infect. 62:280-291.
9. Chen YH, et al. 2012. Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the Tigecycline In Vitro Surveillance in Taiwan study, 2006 to 2010. Antimicrob. Agents Chemother. 56:1452-1457.
10. Chung KP, et al. 2011. Arrival of Klebsiella pneumoniae carbapenemase (KPC)-2 in Taiwan. J. Antimicrob. Chemother. 66:1182-1184.
11. Clinical and Laboratory Standard Institute. 2011. Performance standards for antimicrobial susceptibility testing (M100-S21). Clinical and Laboratory Standards Institute, Wayne, PA.
12. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing (M100-S22). Clinical and Laboratory Standards Institute, Wayne, PA.
13. Dallenne C, Da Costa A, Decré D, Favier C, Arlet G. 2010. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae. J. Antimicrob. Chemother. 65:490-495.
14. Doumith M, Ellington MJ, Livermore DM, Woodford N. 2009. Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK. J. Antimicrob. Chemother. 63:659-667.
15. European Society of Clinical Microbiology and Infectious Diseases. 2011. Clinical breakpoints. In European Committee on Antimicrobial Susceptibility Testing, London, United Kingdom. http://www.eucast.org/.
16. Food and Drug Administration. 2011. Class II special controls guidance document: antimicrobial susceptibility test (AST) systems. U.S. Department of Health and Human Services, Food and Drug Administration, Washington, DC. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ ucm080564.htm. Accessed 22 March 2012.
17. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. 2009. Risk factors and clinical impact of Klebsiella pneumoniae carbapen-emase- producing K. pneumoniae. Infect. Control Hosp. Epidemiol. 30:1180-1185.
18. Hawser SP, et al. 2011. Susceptibility of Klebsiella pneumoniae isolates from intra-abdominal infections and molecular characterization of ertapenem-resistant isolates. Antimicrob. Agents Chemother. 55:3917-3921.
19. Hsu MS, et al. 2011. In vitro susceptibilities of clinical isolates of ertap-enem- non-susceptible Enterobacteriaceae to nemonoxacin, tigecycline, fosfomycin and other antimicrobial agents. Int. J. Antimicrob. Agents 37:276-278.
20. Hu F, et al. 2012. Emergence of carbapenem-resistant clinical Enterobacteriaceae isolates from a teaching hospital in Shanghai, China. J. Med. Microbiol. 61:132-136.
21. Hussein K, et al. 2009. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect. Control Hosp. Epidemiol. 30:666-671.
22. Lai CC, et al. 2011. Pelvic abscess caused by New Delhi metallo-β- lactamase-1-producing Klebsiella oxytoca in Taiwan in a patient who underwent renal transplantation in China. Diagn. Microbiol. Infect. Dis. 71:474-475.
23. Lascols C, et al. 2011. Increasing prevalence and dissemination of NDM-1 metallo-β-lactamase in India: data from the SMART study (2009). J. Antimicrob. Chemother. 66:1992-1997.
24. Leavitt A, et al. 2009. Ertapenem resistance among extended-spectrum- beta- lactamase-producing Klebsiella pneumoniae isolates. J. Clin. Microbiol. 47:969-974.
25. Lomaestro BM, Tobin EH, Shang W, Gootz T. 2006. The spread of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae to upstate New York. Clin. Infect. Dis. 43:e26-e28.
26. Marchaim D, Navon-Venezia S, Schwaber MJ, Carmeli Y. 2008. Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob. Agents Chemother. 52:1413-1418. (Pubitemid 351522007)
27. Nordmann P, Naas T, Poirel L. 2011. Global spread of carbapenemase- producing Enterobacteriaceae. Emerg. Infect. Dis. 17:1791-1798.
28. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. 2008. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect. Control Hosp. Epidemiol. 29:1099-1106.
29. Qi Y, et al. 2011. ST11, the dominant clone of KPC-producing Klebsiella pneumoniae in China. J. Antimicrob. Chemother. 66:307-312.
30. Queenan AM, Bush K. 2007. Carbapenemases: the versatile betalactamases. Clin. Microbiol. Rev. 20:440-458.
31. Steinmann J, et al. 2011. Outbreak due to a Klebsiella pneumoniae strain harbouring KPC-2 and VIM-1 in a German university hospital, July 2010 to January 2011. Euro Surveill. 16(33):pii=19944.
32. Tseng SH, Lee CM, Lin TY, Chang SC, Chang FY. 2011. Emergence and spread of multi-drug resistant organisms: think globally and act locally. J. Microbiol. Immunol. Infect. 44:157-165.
33. Weisenberg SA, Morgan DJ, Espinal-Witter R, Larone DH. 2009. Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem. Diagn. Microbiol. Infect. Dis. 64:233-235.
34. Won SY, et al. 2011. Emergence and rapid regional spread of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. Clin. Infect. Dis. 53:532-540.
35. Woodford N, et al. 2004. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York medical center. Antimicrob. Agents Chemother. 48 :4793-4799. (Pubitemid 39577686)
36. Yan JJ, Wu JJ, Lee CC, Ko WC, Yang FC. 2010. Prevalence and characteristics of ertapenem-nonsusceptible Escherichia coli in a Taiwanese university hospital, 1999 to 2007. Eur. J. Clin. Microbiol. Infect. Dis. 29:1417-1425.
37. Yang FC, Yan JJ, Hung KH, Wu JJ. 2012. Characterization of ertapenemresistant Enterobacter cloacae in a Taiwanese university hospital. J. Clin. Microbiol. 50:223-226.
38. Zarfel G, et al. 2011. Emergence of carbapenem-resistant Enterobacteriaceae in Austria, 2001-2010. Clin. Microbiol. Infect. 17:E5-E8.
39. Zarkotou O, et al. 2010. Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study. J. Clin. Microbiol. 48:2271-2274.